PharmAthene, Inc. — Q1 2012 Form 10-Q
Company identity: The request metadata names Altimmune, Inc., but the supplied filing is for PharmAthene, Inc. This summary reflects the filing provided. Reporting period: three months ended March 31, 2012; financial statements are unaudited.
Business context
PharmAthene was a biodefense company developing medical countermeasures, including SparVax anthrax vaccine, Valortim anthrax antibody, and rBChE for nerve-agent exposure. Revenue came primarily from U.S. government contracts and grants. The filing reports one business segment.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $6.15 million | $6.34 million |
| Operating expenses | $7.74 million | $10.88 million |
| Operating loss | $1.59 million | $4.54 million |
| Net loss | $2.68 million; $0.06 per share | $2.08 million; $0.04 per share |
| Operating margin | Approximately -25.9% | Approximately -71.6% |
| Operating cash flow | $0.79 million provided | $2.09 million used |
| Cash and cash equivalents | $15.30 million at March 31 | $11.24 million at December 31, 2011 |
Gross margin is not separately reported. The increase in net loss despite lower operating expenses primarily reflected a $0.99 million noncash loss from revaluing warrant-related derivative liabilities, versus a $2.49 million noncash gain in Q1 2011, and $0.15 million of income tax expense. The tax expense arose from deferred tax accounting related to goodwill.
At March 31, 2012, current assets were $21.53 million and current liabilities were $5.31 million. The balance sheet included $2.50 million of term debt and $0.86 million drawn on a revolving facility; total liabilities were $10.98 million. Stockholders’ equity was $13.77 million. Cash increased during the quarter in part because of new borrowing and a $0.8 million operating cash contribution; receivable collections and timing also affected operating cash flow.
Changes and financing
- Revenue declined about 3% year over year. SparVax revenue was approximately $5.2 million versus $5.4 million; milestone revenue was $0.9 million versus $1.3 million. rBChE contributed approximately $0.8 million, compared with none in Q1 2011, while Valortim revenue declined to $0.1 million from $0.8 million.
- Research and development expense fell to $4.71 million from $5.82 million, primarily because Valortim work under a NIAID contract ended, internal discretionary R&D was reduced, and SparVax manufacturing activity declined. General and administrative expense fell to $2.95 million from $4.94 million, mainly due to lower SIGA litigation legal fees.
- On March 30, PharmAthene entered a senior secured GE Capital facility: a $2.5 million term loan and a receivables-based revolver of up to $5 million. Approximately $0.9 million was drawn on the revolver, with about $1.7 million additional borrowing availability reported based on the borrowing base. The term loan carries a fixed 10.14% rate; the revolver rate was 6.5% at closing and is variable. Both mature in September 2015.
- The facility is secured by substantially all assets, including proceeds from intellectual property, and contains financial and other covenants, default and acceleration provisions, and prepayment premiums. The company issued GE Capital warrants for 46,584 shares at $1.61 per share.
Outlook, risks and contingencies
Management expected cash on hand, available revolver capacity, receivable collections, and revenue under existing contracts to fund operations and capital requirements through at least March 31, 2013. The company stated it had not generated positive operating cash flow since inception and expected to continue needing external financing. Management cited potential funding constraints, government budget changes, contract timing, and uncertainty in capital markets.
- Management said additional government funding for Valortim was unlikely during government fiscal 2012, although work continued under a DoD contract through October 2012. The company was exploring possible BARDA funding.
- The Delaware Court of Chancery had awarded PharmAthene a right to 50% of net profits from SIGA’s ST-246 and related products for 10 years after commercial sales begin and SIGA earns $40 million in net profits, plus one-third of reasonable legal and expert fees. SIGA intended to appeal; the outcome and timing or amount of any proceeds were uncertain.
- Product candidates remained subject to development, manufacturing, clinical-safety and efficacy, regulatory-approval, and commercialization risks. The filing notes that significant studies and manufacturing work remained; future Valortim funding was uncertain.
- Cost-plus government contract payments are subject to audit, though management did not expect resulting adjustments to have a material effect. The filing also describes possible registration-maintenance penalties, with maximum obligations stated as approximately $0.2 million initially and approximately $0.2 million per month while a failure continues.
- Contractual obligations totaled $18.63 million, including $11.93 million for research and development agreements, $4.20 million for facility leases, and $2.50 million of term-loan principal. The company reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is PharmAthene’s, not an Altimmune filing.
- Review the GE Capital agreement, borrowing-base availability, covenants, collateral, amortization schedule, and default provisions; the filing reports different debt classifications on the balance sheet and describes a receivables-dependent revolver.
- Check subsequent developments in the SIGA appeal and whether any award or related proceeds became realizable.
- Track government contract awards, milestones, receivable collections, and funding for Valortim and the other development programs.
- Assess cash use and financing needs against management’s stated liquidity runway, which is an expectation rather than a guarantee.